The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Roche’s cobas SARS-CoV-2 Test for asymptomatic people and those with suspected Covid-19.

Authorised to be used on cobas 6800/8800 Systems, the real-time reverse transcription polymerase chain reaction (RT-PCR) test is indicated to qualitatively identify SARS-CoV-2 nucleic acids.

Test specimens can be self-collected anterior nasal swab samples obtained on-site under the surveillance of a healthcare worker or nasal, nasopharyngeal and oropharyngeal swab samples collected by healthcare workers.

The cobas SARS-CoV-2 test is indicated for use in people who are suspected of having Covid-19 as well as for asymptomatic individuals or those with further reasons to suspect the disease.

Roche noted that the EUA supports the US Centers for Disease Control and Prevention’s guidance to scale up Covid-19 testing to asymptomatic individuals. The aim is to mitigate the disease spread.

The authorisation is applicable to pooled specimens of up to six individual samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche diagnostics solutions molecular lab head Cindy Perettie said: “One of the key strategies to reduce Covid-19 transmission is to stop the silent spread of disease early.

“Expanding highly sensitive testing to include people who are at risk of exposure but do not show symptoms will help guide contact tracing, isolation and surveillance requirements, which are crucial for public health and the safe reopening of communities.”

The company noted that asymptomatic testing using this test is available in CE mark accepting countries.

In March, Roche launched a new SARS-CoV-2, research use only laboratory test to help monitor emerging mutations of coronavirus.

Separately, binx health has submitted a EUA application to the FDA for its CRISPR-based point-of-care (POC) Covid-19 test.

Named ‘binx io’, the test is a Clinical Laboratory Improvement Amendments-waived platform for molecular identification of chlamydia and gonorrhoea in approximately 30 minutes.

The company modified this single-use cartridge for testing RNA-based targets. Sherlock Biosciences’ CRISPR technology was combined with binx’s electrochemical detection to develop this Covid-19 testing tool.